Erratum note: Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China

Erratum to: “Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China (https://doi.org/10.54844/hd.2023.0362).

ERRATUM REASON

Due to the author's lack of careful proofreading, this article was accidentally missing the “Table 6 base case results”. In the last paragraph of Costs of Model Input section, the “Table 4” should be written as “Table 5” (A summary of cost inputs used in the model is showed in Table 5). In the Base case analysis of Results section, the “Table 5” should be written as “Table 6” (Table 6 shows the detailed results of the base case analysis). In the results section of the abstract, the “CNY 173,575” should be written as “CNY 173,757” (ziprasidone generated 4.28 QALYs with cost of CNY 173,757).

The authors and editors apologize for this error and state that this does not change the scientific conclusions of the article in any way and does not involve any academic or ethical issues.